Patents by Inventor Keith Black
Keith Black has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11630061Abstract: Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.Type: GrantFiled: April 15, 2020Date of Patent: April 18, 2023Assignees: Black Light Surgical, Inc., Cedars-Sinai Medical CenterInventors: Pramod Butte, Keith Black, Jack Kavanaugh, Bartosz Bortnik, Zhaojun Nie
-
Publication number: 20220276167Abstract: Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.Type: ApplicationFiled: January 19, 2022Publication date: September 1, 2022Inventors: Pramod Butte, Keith Black, Jack Kavanaugh, Bartosz Bortnik, Zhaojun Nie
-
Patent number: 11058720Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.Type: GrantFiled: May 22, 2017Date of Patent: July 13, 2021Assignee: CEDARS-SINAI MEDICAL CENTERInventors: Maya Koronyo, Altanchimeg Rentsendorj, Yosef Koronyo, Keith Black
-
Publication number: 20200330592Abstract: The present disclosure relates to methods of treating, delaying the onset, alleviating a symptom, and/or deterring the progression of a disease related to beta amyloid deposits, neurological damage, tauopathy, and/or neurodegeneration by administering a myelin sheath protein and an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta. The present disclosure relates to methods of using a myelin sheath protein and/or an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta, to treat or to slow the progression of a disease characterized in part by beta amyloid (A) expression or activity, or by aberrant deposition of beta amyloid in a subject, such as in Alzheimers disease, and the pathologies associated with such a disease, including for example, behavioral changes or cognitive dysfunction associated with Alzheimers disease.Type: ApplicationFiled: October 8, 2018Publication date: October 22, 2020Inventor: Keith BLACK
-
Publication number: 20200330581Abstract: Disclosed herein are methods of treating a brain cancer comprising administering to a subject in need thereof a viral composition comprising a flavivirus or portion of a flavivirus wherein the flavivirus is engineered to comprise a heterologous nucleic acid sequence encoding a suicide gene. In some embodiments, the brain cancer is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, meningioma, schwannoma, craniopharyngioma, germinoma, and pineocytoma. In some embodiments the flavivirus comprises Zika virus, spondweni virus, kedougous virus, or a combination thereof. In some embodiments, the flavivirus comprises Zika virus. In some embodiments, the suicide gene encodes a protein that converts a prodrug into a cytotoxic agent. In some embodiments, the viral composition is administered in combination with the immunostimulatory agent.Type: ApplicationFiled: October 8, 2018Publication date: October 22, 2020Inventor: Keith BLACK
-
Publication number: 20200319108Abstract: Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.Type: ApplicationFiled: April 15, 2020Publication date: October 8, 2020Inventors: Pramod Butte, Keith Black, Jack Kavanaugh, Bartosz Bortnik, Zhaojun Nie
-
Patent number: 10656089Abstract: Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.Type: GrantFiled: March 31, 2017Date of Patent: May 19, 2020Assignees: Black Light Surgical, Inc., Cedars-Sinai Medical CenterInventors: Pramod Butte, Keith Black, Jack Kavanaugh, Bartosz Bortnik, Zhaojun Nie
-
Patent number: 10512699Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.Type: GrantFiled: October 31, 2017Date of Patent: December 24, 2019Assignees: Cedars-Sinai Medical Center, Yeda Research and Development Co., Ltd.Inventors: Yosef Koronyo, Maya Koronyo, Keith Black, Michal Schwartz, Daniel L. Farkas
-
Publication number: 20190290687Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.Type: ApplicationFiled: May 22, 2017Publication date: September 26, 2019Inventors: Maya KORONYO, Altanchimeg RENTSENDORJ, Yosef KORONYO, Keith BLACK
-
Publication number: 20190022255Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.Type: ApplicationFiled: October 31, 2017Publication date: January 24, 2019Applicants: Cedars-Sinai Medical Center, Yeda Research and Development, Co., Ltd.Inventors: Yosef Koronyo, Maya Koronyo, Keith Black, Michal Schwartz, Daniel L. Farkas
-
Publication number: 20180015047Abstract: Provided herein are methods and compositions for removal of a substance using magnetic nanoparticles comprising a tagging element capable of targeting the nanoparticle to the substance. Further provided herein are methods and devices for removal of magnetic nanoparticle bound substances using a magnetic field generating device.Type: ApplicationFiled: July 14, 2017Publication date: January 18, 2018Inventors: Keith Black, Jack Kavanaugh
-
Publication number: 20170284940Abstract: Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.Type: ApplicationFiled: March 31, 2017Publication date: October 5, 2017Inventors: Pramod BUTTE, Keith BLACK, Jack KAVANAUGH
-
Patent number: 8562964Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.Type: GrantFiled: April 29, 2011Date of Patent: October 22, 2013Assignees: Cedars-Sinai Medical Center, Arrogene Nanotechnology, Inc.Inventors: Julia Y. Ljubimova, Keith Black, Eggehard Holler
-
Publication number: 20110212048Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.Type: ApplicationFiled: April 29, 2011Publication date: September 1, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Julia Y. Ljubimova, Keith Black, Eggehard Holler
-
Patent number: 7838449Abstract: A dryer sheet substrate is provided having improved loft and reduced fuzz wherein the substrate comprises relatively low denier bicomponent fibers. The bicomponent fibers may comprise two or more polymers having different melting temperatures, with the relatively lower melting temperature polymer making up at least a portion of the outer surface of the fiber. Upon heating to a sufficient temperature, the lower melting temperature fibers may soften and melt, providing bonding at crossover points of the fibers in the laid web. The web indicates advantageous characteristics with respect to thickness (loft), fuzz factor and ability to absorb a fabric treating composition.Type: GrantFiled: May 29, 2008Date of Patent: November 23, 2010Assignee: Freudenberg Spunweb CompanyInventors: Samuel Keith Black, Terezie Zapletalova, John McNabb, Jeffrey Stine
-
Publication number: 20090297809Abstract: A dryer sheet substrate is provided having improved loft and reduced fuzz wherein the substrate comprises relatively low denier bicomponent fibers. The bicomponent fibers may comprise two or more polymers having different melting temperatures, with the relatively lower melting temperature polymer making up at least a portion of the outer surface of the fiber. Upon heating to a sufficient temperature, the lower melting temperature fibers may soften and melt, providing bonding at crossover points of the fibers in the laid web. The web indicates advantageous characteristics with respect to thickness (loft), fuzz factor and ability to absorb a fabric treating composition.Type: ApplicationFiled: May 29, 2008Publication date: December 3, 2009Applicant: FREUDENBERG NONWOVENS, L.P.Inventors: Samuel Keith Black, Terezie Zapletalova, John McNabb, Jeffrey Stine
-
Publication number: 20080166939Abstract: The present disclosure provides an acoustical substrate including nonwoven material which includes a two component adhesive system which may be treated with a fluid repelling compound. The two component adhesive system may comprise two adhesive components having different melting points to allow for flexible industrial post processing and laminating. The adhesives may be applied by a variety of methods and may exist in the substrate in, e.g., either discrete or continuous web forms.Type: ApplicationFiled: January 9, 2007Publication date: July 10, 2008Inventors: Keith Black, Michael L. Reynolds
-
Publication number: 20080050337Abstract: Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as NS-1619, EBIO, a guanylyl cyclase activating protein, an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject.Type: ApplicationFiled: September 17, 2007Publication date: February 28, 2008Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Keith Black, Nagendra Ningaraj
-
Publication number: 20080003907Abstract: A composite facing material is disclosed that may be used in combination with, e.g. foam, fibers and/or shoddy in a vehicular application. The composite may provide heat insulation and/or sound attenuation in a vehicular trim panel. The facing material may include a layer of staple fibers with a spunbonded continuous filament web layer. The layers may be intermittently thermally bonded in a desired pattern.Type: ApplicationFiled: June 28, 2006Publication date: January 3, 2008Inventors: Samuel Keith Black, Quentin Kampf, Sean Morin
-
Publication number: 20070259008Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.Type: ApplicationFiled: December 3, 2004Publication date: November 8, 2007Inventors: Julia Ljubimova, Keith Black, Eggehard Holler